Riccardo Leni
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Riccardo Leni has a total of 95 co-authors. Here are the top co-authors by number of shared publications:
- Alberto Briganti
Vita-Salute San Raffaele University
6 shared publications - Francesco Montorsi
Vita-Salute San Raffaele University, Milan, Italy
6 shared publications Alberto Briganti
Division of Experimental Oncology, Department of Urology IRCCS San Raffaele Scientific Institute Milan Italy
4 shared publications- Andrea Salonia
Department of Experimental Oncology/Unit of Urology, URI IRCCS Ospedale San Raffaele Milan Italy
4 shared publications Francesco Montorsi
Division of Experimental Oncology, Department of Urology, IRCCS San Raffaele Scientific Institute Milan Italy
4 shared publications- Marco Bandini
Department of Experimental Oncology/Unit of Urology, URI IRCCS Ospedale San Raffaele Milan Italy
4 shared publications
Latest Publications
- 16 September 2026
- Published by Wiley in BJU International
Is Gleason pattern 3 cancer? Molecular features do not distinguish pattern 3 from benign tissue
- 16 September 2026
- Published by Wiley in BJU International
Is Gleason pattern 3 cancer? Molecular features do not distinguish pattern 3 from benign tissue
- 29 May 2025
- Published by Wiley in BJU International
- Vol. 136 (3) , 500-506
Magnetic resonance imaging for long‐term active surveillance biopsy decision‐making
Objectives: To evaluate whether long‐term magnetic resonance imaging (MRI) findings, alone or in combination with prostate‐specific antigen (PSA) density or the result of prior surveillance biopsies, could be used to omit biopsies occurring after patients have been on active surveillance (AS) for ≥5 years. Patients and Methods: Analysis of a single‐institution AS cohort of patients with Grade Group (GG) 1 prostate cancer who underwent a scheduled 6‐year MRI and biopsy. Multivariable logistic regression was used to test the association between the Prostate Imaging‐Reporting and Data System (PI‐RADS) score, PSA density, status of prior AS biopsy, and reclassification to GG ≥2. We then analysed how many GG ≥2 cancers would be missed if the 6‐year biopsy was avoided based on significant predictors. Results: In all, 49 of 221 men (22%) were reclassified to GG ≥2. PSA density and PI‐RADS scores 4–5 were significant predictors; a prior negative AS biopsy was inversely associated with GG ≥2. The risk of missing GG ≥2 if the 6‐year biopsy is omitted in men with an unsuspicious MRI (PI‐RADS 1–2) was 12% (95% confidence interval [CI] 5.3–19%). After testing combinations of MRI findings, PSA density, and the status of the prior biopsy, we found the lowest risk of GG ≥2 in patients with a prior negative biopsy and PSA density of <0.10 ng/mL/cc (5.3%, 95% CI 1.5–10%). Conclusions: An unsuspicious MRI at 6 years is not enough alone to omit the 6‐year AS biopsy under current guidelines. Combining MRI findings, PSA density, and prior negative AS biopsies is a promising strategy to tailor surveillance intensity. Our findings should be replicated in larger cohorts prior to implementation in clinical practice.
- 29 May 2025
- Published by Wiley in BJU International
- Vol. 136 (3) , 500-506
Magnetic resonance imaging for long‐term active surveillance biopsy decision‐making
Objectives: To evaluate whether long‐term magnetic resonance imaging (MRI) findings, alone or in combination with prostate‐specific antigen (PSA) density or the result of prior surveillance biopsies, could be used to omit biopsies occurring after patients have been on active surveillance (AS) for ≥5 years. Patients and Methods: Analysis of a single‐institution AS cohort of patients with Grade Group (GG) 1 prostate cancer who underwent a scheduled 6‐year MRI and biopsy. Multivariable logistic regression was used to test the association between the Prostate Imaging‐Reporting and Data System (PI‐RADS) score, PSA density, status of prior AS biopsy, and reclassification to GG ≥2. We then analysed how many GG ≥2 cancers would be missed if the 6‐year biopsy was avoided based on significant predictors. Results: In all, 49 of 221 men (22%) were reclassified to GG ≥2. PSA density and PI‐RADS scores 4–5 were significant predictors; a prior negative AS biopsy was inversely associated with GG ≥2. The risk of missing GG ≥2 if the 6‐year biopsy is omitted in men with an unsuspicious MRI (PI‐RADS 1–2) was 12% (95% confidence interval [CI] 5.3–19%). After testing combinations of MRI findings, PSA density, and the status of the prior biopsy, we found the lowest risk of GG ≥2 in patients with a prior negative biopsy and PSA density of <0.10 ng/mL/cc (5.3%, 95% CI 1.5–10%). Conclusions: An unsuspicious MRI at 6 years is not enough alone to omit the 6‐year AS biopsy under current guidelines. Combining MRI findings, PSA density, and prior negative AS biopsies is a promising strategy to tailor surveillance intensity. Our findings should be replicated in larger cohorts prior to implementation in clinical practice.
- 7 May 2025
- Published by Springer Nature
- p. 361-370
Transperineal and Transrectal Biopsy Techniques in Men on Active Surveillance for Early Prostate Cancer
- 7 May 2025
- Published by Springer Nature
- p. 361-370
Transperineal and Transrectal Biopsy Techniques in Men on Active Surveillance for Early Prostate Cancer
- Open Access
- 12 February 2025
- Published by Elsevier in European Urology Open Science
- Vol. 72, 46-53
Confirmatory Biopsy Outcomes in Patients with Grade Group 2 Prostate Cancer: Implications for Early Management
- 12 February 2025
- Published by Elsevier in European Urology Open Science
- Vol. 72, 46-53
Open AccessConfirmatory Biopsy Outcomes in Patients with Grade Group 2 Prostate Cancer: Implications for Early Management
- 15 December 2024
- Published by Elsevier in European Urology Oncology
- Vol. 8 (1) , 215
Re: Julien Anract, Clément Klein, Ugo Pinar, Morgan Rouprêt, Nicolas Barry Delongchamps, Grégoire Robert. Incidental Prostate Cancer in Patients Undergoing Surgery for Benign Prostatic Hyperplasia: A Predictive Model. Eur Urol Oncol. 2025;8:145–51
- 15 December 2024
- Published by Elsevier in European Urology Oncology
- Vol. 8 (1) , 215
Re: Julien Anract, Clément Klein, Ugo Pinar, Morgan Rouprêt, Nicolas Barry Delongchamps, Grégoire Robert. Incidental Prostate Cancer in Patients Undergoing Surgery for Benign Prostatic Hyperplasia: A Predictive Model. Eur Urol Oncol. 2025;8:145–51
- 1 November 2024
- Published by Wolters Kluwer Health in Journal of Urology
- Vol. 212 (5) , 760-761
Letter: Impact of Family History and Germline Genetic Risk Single Nucleotide Polymorphisms on Long-Term Outcomes of Favorable-Risk Prostate Cancer
- 1 November 2024
- Published by Wolters Kluwer Health in Journal of Urology
- Vol. 212 (5) , 760-761
Letter: Impact of Family History and Germline Genetic Risk Single Nucleotide Polymorphisms on Long-Term Outcomes of Favorable-Risk Prostate Cancer
- 1 November 2024
- Published by Wolters Kluwer Health in Journal of Urology
- Vol. 212 (5) , 692-700
Management and Oncologic Outcomes of Incidental Prostate Cancer After Transurethral Resection of the Prostate in Denmark
Approximately 1 in 10 patients without prior prostate biopsy undergoing surgery for lower urinary tract symptoms harbor incidental prostate cancer, however, practice guidelines do not provide recommendations for its management. We aimed at describing the oncologic outcomes of patients with grade group (GG) 1 and 2 prostate cancer diagnosed at transurethral resection of the prostate (TURP). This was a nationwide population-based observational study of patients undergoing TURP in Denmark from 2006 to 2022 using the Danish Prostate Registry. We estimated the cumulative incidence of further biopsies and magnetic resonance imaging (MRI), curative treatment, endocrine treatment, and cause-specific mortality with competing risk analyses. Among 24,494 patients who underwent TURP, there were 1016 men with GG 1 and 381 with GG 2. The 5-year cumulative incidence of further MRIs or biopsies was 36% (95% CI 33%-39%) for GG 1, and 30% (95% CI 25%-34%) for GG 2. Fifteen-year prostate cancer mortality was 8.4% (95% CI 5.3%-11%) for GG 1, and 14% (7.5%-21%) for GG 2. A total of 270 men with GG 1 underwent a biopsy after the TURP, and 162 (60%) had no cancer, in this group, prostate cancer mortality after 15 years was 0.6% (95% CI 0%-1.8%). Men with post-TURP biopsy of GG ≥ 2 had a prostate cancer mortality of 30% (95% CI 9%-50%) 15 years post-TURP. The major limitation was the heterogeneous follow-up, which could lead to an overestimation of prostate cancer mortality compared to a more standardized follow-up. We observed high prostate cancer mortality after TURP with GG 1 or 2, likely due to unsampled high-grade cancer in the peripheral zone. Patients with incidental prostate cancer should be further investigated to rule out high-grade cancer. For patients with GG 1 on TURP, once a subsequent biopsy does not show cancer, follow-up should be lessened similar to that of patients with an initial non-malignant biopsy.
- 1 November 2024
- Published by Wolters Kluwer Health in Journal of Urology
- Vol. 212 (5) , 692-700
Management and Oncologic Outcomes of Incidental Prostate Cancer After Transurethral Resection of the Prostate in Denmark
Approximately 1 in 10 patients without prior prostate biopsy undergoing surgery for lower urinary tract symptoms harbor incidental prostate cancer, however, practice guidelines do not provide recommendations for its management. We aimed at describing the oncologic outcomes of patients with grade group (GG) 1 and 2 prostate cancer diagnosed at transurethral resection of the prostate (TURP). This was a nationwide population-based observational study of patients undergoing TURP in Denmark from 2006 to 2022 using the Danish Prostate Registry. We estimated the cumulative incidence of further biopsies and magnetic resonance imaging (MRI), curative treatment, endocrine treatment, and cause-specific mortality with competing risk analyses. Among 24,494 patients who underwent TURP, there were 1016 men with GG 1 and 381 with GG 2. The 5-year cumulative incidence of further MRIs or biopsies was 36% (95% CI 33%-39%) for GG 1, and 30% (95% CI 25%-34%) for GG 2. Fifteen-year prostate cancer mortality was 8.4% (95% CI 5.3%-11%) for GG 1, and 14% (7.5%-21%) for GG 2. A total of 270 men with GG 1 underwent a biopsy after the TURP, and 162 (60%) had no cancer, in this group, prostate cancer mortality after 15 years was 0.6% (95% CI 0%-1.8%). Men with post-TURP biopsy of GG ≥ 2 had a prostate cancer mortality of 30% (95% CI 9%-50%) 15 years post-TURP. The major limitation was the heterogeneous follow-up, which could lead to an overestimation of prostate cancer mortality compared to a more standardized follow-up. We observed high prostate cancer mortality after TURP with GG 1 or 2, likely due to unsampled high-grade cancer in the peripheral zone. Patients with incidental prostate cancer should be further investigated to rule out high-grade cancer. For patients with GG 1 on TURP, once a subsequent biopsy does not show cancer, follow-up should be lessened similar to that of patients with an initial non-malignant biopsy.
- Open Access
- 20 August 2024
- Published by Elsevier in European Urology Open Science
- Vol. 68, 10-17
Oncologic Outcomes of Incidental Versus Biopsy-diagnosed Grade Group 1 Prostate Cancer: A Multi-institutional Study
- 20 August 2024
- Published by Elsevier in European Urology Open Science
- Vol. 68, 10-17
Open AccessOncologic Outcomes of Incidental Versus Biopsy-diagnosed Grade Group 1 Prostate Cancer: A Multi-institutional Study
- Open Access
- 1 January 2023
- Published by XMLink in The World Journal of Men's Health
- Vol. 41 (3) , 466-481
The Complex Interplay between Serum Testosterone and the Clinical Course of Coronavirus Disease 19 Pandemic: A Systematic Review of Clinical and Preclinical Evidence
Leni R, et al. World J Mens Health. 2023 Jan;41:e15. https://doi.org/10.5534/wjmh.220143
- 1 January 2023
- Published by XMLink in The World Journal of Men's Health
- Vol. 41 (3) , 466-481
Open AccessThe Complex Interplay between Serum Testosterone and the Clinical Course of Coronavirus Disease 19 Pandemic: A Systematic Review of Clinical and Preclinical Evidence
Leni R, et al. World J Mens Health. 2023 Jan;41:e15. https://doi.org/10.5534/wjmh.220143
- Open Access
- 10 September 2021
- Published by MDPI AG in Société Internationale d’Urologie Journal
- No. 5,p. 282-298
Dissecting patterns of care in patients with variant histology of bladder cancer and lymph node invasion
Objectives Lymph node invasion (LNI) is related to long-term survival in patients with muscle-invasive bladder cancer. However, in the case of variant histology (VH), data on pelvic lymph node dissection (PLND) and LNI are sparse. We described the pattern of care of PLND in patients with VHs of bladder cancer, exploring predictors of LNI. Methods Using the 2001–2016 SEER registry, 20 767 bladder cancer patients who underwent PLND were identified. Included histological variants were pure urothelial carcinoma (UC), micropapillary UC, sarcomatoid UC, lymphoepithelioma-like UC, adenocarcinoma, sarcoma, giant and spindle cell carcinoma, squamous cell carcinoma (SCC), and neuroendocrine tumor. Uni- and multivariable logistic regression analyses tested for LNI predictors. Cox regression was used to test for predictors of overall mortality (OM) among both LNI positive and LNI negative patients. Results Overall, 2464 (11.9%) harbored a VH. On multivariate analysis, only micropapillary UC was associated with higher risk (OR = 3.39) of LNI. This association was maintained when only the subset of patients treated without perioperative chemotherapy were analyzed (OR = 3.30). Similarly, higher T stage (T2 stage OR = 2.24; T3–4 stage OR = 9.44) and the use of chemotherapy (OR = 2.29) were associated with a higher risk of LNI. Among patients with LNI (5299, 25.5%), SCC (HR = 1.87), T3–4 stage (HR = 1.94), age at diagnosis (HR = 1.01) and geographic region (south) (HR = 1.22) were predictors of higher risk of OM. Conversely, chemotherapy (HR = 0.69) and number of removed LN (HR = −0.99) were associated with lower risk of OM. Finally, in a subgroup of patients without LNI, sarcomatoid UC (HR = 1.58) and giant and spindle cell carcinoma (HR = 1.83) were the only VH predictors of OM. Conclusions We described different patterns of care in patients with VHs of bladder cancer. Micropapillary UC was an independent risk factor for LNI. Among patients harboring LNI, those with SCC VH had higher OM compared to pure UC. Conversely, sarcomatoid UC and giant and spindle cell carcinoma were predictors of OM in patients without nodal involvement.
- 10 September 2021
- Published by MDPI AG in Société Internationale d’Urologie Journal
- No. 5,p. 282-298
Open AccessDissecting patterns of care in patients with variant histology of bladder cancer and lymph node invasion
Objectives Lymph node invasion (LNI) is related to long-term survival in patients with muscle-invasive bladder cancer. However, in the case of variant histology (VH), data on pelvic lymph node dissection (PLND) and LNI are sparse. We described the pattern of care of PLND in patients with VHs of bladder cancer, exploring predictors of LNI. Methods Using the 2001–2016 SEER registry, 20 767 bladder cancer patients who underwent PLND were identified. Included histological variants were pure urothelial carcinoma (UC), micropapillary UC, sarcomatoid UC, lymphoepithelioma-like UC, adenocarcinoma, sarcoma, giant and spindle cell carcinoma, squamous cell carcinoma (SCC), and neuroendocrine tumor. Uni- and multivariable logistic regression analyses tested for LNI predictors. Cox regression was used to test for predictors of overall mortality (OM) among both LNI positive and LNI negative patients. Results Overall, 2464 (11.9%) harbored a VH. On multivariate analysis, only micropapillary UC was associated with higher risk (OR = 3.39) of LNI. This association was maintained when only the subset of patients treated without perioperative chemotherapy were analyzed (OR = 3.30). Similarly, higher T stage (T2 stage OR = 2.24; T3–4 stage OR = 9.44) and the use of chemotherapy (OR = 2.29) were associated with a higher risk of LNI. Among patients with LNI (5299, 25.5%), SCC (HR = 1.87), T3–4 stage (HR = 1.94), age at diagnosis (HR = 1.01) and geographic region (south) (HR = 1.22) were predictors of higher risk of OM. Conversely, chemotherapy (HR = 0.69) and number of removed LN (HR = −0.99) were associated with lower risk of OM. Finally, in a subgroup of patients without LNI, sarcomatoid UC (HR = 1.58) and giant and spindle cell carcinoma (HR = 1.83) were the only VH predictors of OM. Conclusions We described different patterns of care in patients with VHs of bladder cancer. Micropapillary UC was an independent risk factor for LNI. Among patients harboring LNI, those with SCC VH had higher OM compared to pure UC. Conversely, sarcomatoid UC and giant and spindle cell carcinoma were predictors of OM in patients without nodal involvement.